NEXT MILESTONE FOR OUR INNOVATIVE TECHNOLOGY OF PRESERVING CELL THERAPEUTICS
Pilot Facility Enables Development of Proprietary Process for Preserving Keratinocytes
Graz, March 2024 – EVOMEDIS has significantly expanded its technical capabilities in freeze-drying and strengthened its internal expert team. The goal is to advance the development of innovative cell therapeutics for the treatment of burn injuries and
chronic wounds. At the core of this milestone is a proprietary process that preserves human primary keratinocytes through freeze-drying, enabling storage for up to four months at 4 °C without loss of therapeutic potency. The resulting product, EVOCellic, is designed for clinical use in severe skin injuries.
With the commissioning of a pilot-scale freeze-dryer, development work can now be carried out in-house under aseptic conditions. The process will later be transferred to a contract research organization (CRO) for GMP-compliant validation and subsequent production of clinical trial material.
“By expanding our technical infrastructure, we are laying the foundation for safe and effective cell therapeutics that can be stored for longer periods and used more flexibly. This is an important step towards the clinical application of EVOCellic,” says Dr. Martin Funk, CEO and founder of EVOMEDIS. Dr. Funk has more than 25 years of experience in biotechnology R&D, has led or founded several companies since 2011, and has held management positions since 1996. He is a co-founder and the CEO of EVOMEDIS since 2020.
About EVOMEDIS
EVOMEDIS develops innovative cell therapies and medical technology solutions for the treatment of complex burn and chronic wounds. The company combines scientific excellence, practical product development, and state-of-the-art production technologies. It's mission is to provide patients with new, effective treatment options and to make a lasting contribution to improving wound care.